FerriIridium: A Lysosome‐Targeting Iron(III)‐Activated Iridium(III) Prodrug for Chemotherapy in Gastric Cancer Cells

Reported is the Fe III ‐activated lysosome‐targeting prodrug FerriIridium for gastric cancer theranostics. It contains a meta ‐imino catechol group that can selectively bond to, and be oxidized by, free Fe III inside the cell. Subsequent oxidative rearrangement releases Fe II and hydrolyses the amine bond under acidic conditions, forming an aminobipyridyl Ir complex and 2‐hydroxybenzoquinone. Thus, Fe II catalyzes the Fenton reaction,...